Neogenomics Inc Stock Research

Market Summary

USD17.28-0.09

Market Closed

-0.52%

NEO Alerts

Big jump in Earnings (Y/Y)
Losses in recent quarter

NEO Stock Price

NEO RSI Chart

NEO Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

-17.59

Price/Sales (Trailing)

4.17

EV/EBITDA

-18.89

Price/Free Cashflow

-26.86

NEO Price/Sales (Trailing)

NEO Profitability

EBT Margin

-31.26%

Return on Equity

-14.45%

Return on Assets

-8.29%

Free Cashflow Yield

-3.72%

NEO Fundamentals

NEO Revenue

Revenue (TTM)

529.8M

Revenue Y/Y

17.11%

Revenue Q/Q

-1.07%

NEO Earnings

Earnings (TTM)

-125.6M

Earnings Y/Y

37.67%

Earnings Q/Q

-35.74%

Price Action

52 Week Range

6.0020.54

(Low)(High)

Last 7 days

-3.7%

Last 30 days

21.1%

Last 90 days

10.1%

Trailing 12 Months

121.0%

NEO Financial Health

Current Ratio

6.73

Debt/Equity

0.51

Debt/Cashflow

-0.14

NEO Investor Care

Shares Dilution (1Y)

1.99%

Peers (Alternatives to Neogenomics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
TMO	230.7B	43.8B	-5.06%	-2.55%	33.15	5.14	6.53%	-9.94%
IQV	36.6B	14.5B	3.00%	-2.89%	34.72	2.53	3.29%	-2.22%
INCY	14.0B	3.4B	-14.52%	-17.83%	43.23	4.13	13.67%	-65.23%
CRL	10.0B	4.1B	3.89%	-12.79%	20.1	2.44	12.73%	17.48%
MID-CAP
MEDP	6.2B	1.6B	-2.93%	52.95%	24.09	3.96	28.83%	28.57%
SYNH	4.3B	5.4B	9.59%	-41.20%	28.88	0.79	1.37%	-38.84%
ARWR	3.6B	272.8M	-0.03%	-1.18%	-23.88	13.15	3.56%	-34.35%
NEO	2.2B	529.8M	21.13%	120.99%	-17.59	4.17	9.02%	-252.50%
SMALL-CAP
AVXL	718.9M	-	15.32%	-1.54%	-13.63	291.16	-34.21%	-22.02%
PGEN	306.6M	23.2M	6.19%	-3.23%	12.35	13.19	-45.75%	126.39%
SRNE	170.9M	-	-71.28%	-88.95%	-0.25	2.64	22.40%	-42.61%
CDXC	106.8M	77.3M	6.72%	-15.88%	-9.98	1.38	10.46%	61.07%
PSNL	90.7M	68.7M	-11.82%	-52.10%	-0.8	1.32	-13.98%	-40.40%

Financials for Neogenomics

Income Statement (Last 12 Months)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	3.9%	529,779,000	509,728,000	496,755,000	489,313,000	485,965,000
Gross Profit	8.8%	204,478,000	187,896,000	176,328,000	174,674,000	183,718,000
Operating Expenses	-0.1%	345,146,000	345,519,000	349,135,000	347,684,000	339,393,000
S&GA Expenses	-0.1%	67,281,000	67,321,000	66,096,000	64,991,000	65,144,000
R&D Expenses	-1.0%	30,008,000	30,326,000	32,164,000	32,261,000	27,130,000
EBITDA	12.3%	-122,464,000	-139,670,000	-122,854,000	-9,986,000	-
EBITDA Margin	14.6%	-0.24	-0.28	-0.25	-0.02	-
Earnings Before Taxes	12.2%	-139,901,000	-159,342,000	-178,022,000	-161,568,000	-47,099,000
EBT Margin	12.8%	-0.31	-0.36	-0.33	-0.10	-
Interest Expenses	-63.0%	1,506,000	4,073,000	5,230,000	5,206,000	-
Net Income	12.9%	-125,637,000	-144,250,000	-163,322,000	-146,818,000	-35,642,000
Net Income Margin	13.9%	-0.28	-0.33	-0.30	-0.07	-
Free Cahsflow	19.6%	-96,884,000	-120,428,000	-119,056,000	-114,503,000	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	-1.8%	1,709	1,740	1,756	1,792	1,830
Current Assets	-3.4%	585	605	603	622	651
Cash Equivalents	4.7%	276	263	266	284	306
Inventory	0.6%	24.00	24.00	24.00	22.00	24.00
Net PPE	0.3%	103	102	107	111	109
Goodwill	0%	523	523	523	527	527
Liabilities	-1.0%	735	742	743	749	755
Current Liabilities	-3.7%	87.00	90.00	85.00	83.00	82.00
Shareholder's Equity	-2.4%	974	998	1,013	1,044	1,075
Retained Earnings	-19.4%	-189	-159	-136	-99.55	-64.24
Additional Paid-In Capital	0.5%	1,167	1,161	1,154	1,147	1,142
Accumulated Depreciation	5.3%	139	132	125	123	116
Shares Outstanding	2.5%	127	124	127	126	125

Cashflow (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	24.8%	-49,645	-65,993	-82,084	-73,579	-57,973
Share Based Compensation	-29.8%	17,327	24,672	30,071	31,028	31,908
Cashflow From Investing	2261.1%	12,207	517	-8,003	-18,491	-465,627
Cashflow From Financing	-39.5%	7,151	11,829	12,487	2,808	206,407

Risks for NEO

What is the probability of a big loss on NEO?

99.2%

Probability that Neogenomics stock will be more than 20% underwater in next one year

66.2%

Probability that Neogenomics stock will be more than 30% underwater in next one year.

30%

Probability that Neogenomics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does NEO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Neogenomics was unfortunately bought at previous high price.

Drawdowns

Returns for NEO

Cumulative Returns on NEO

17.0%

10-Year Cumulative Returns

10.5%

7-Year Cumulative Returns

8.4%

5-Year Cumulative Returns

-14.9%

3-Year Cumulative Returns

What are the long-term rolling returns for NEO?

FIve years rolling returns for Neogenomics.

Annualized Returns

Which funds bought or sold NEO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-23	ROYCE & ASSOCIATES LP	reduced	-5.65	3,431,510	7,844,080	0.08%
2023-05-22	AMERIPRISE FINANCIAL INC	reduced	-21.47	5,483,450	16,911,400	0.01%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	unchanged	-	222,000	1,935,000	-%
2023-05-18	JPMORGAN CHASE & CO	reduced	-20.38	6,958,000	20,865,000	-%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	added	112	3,369,000	4,488,000	0.01%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	added	12.83	704,000	3,526,000	-%
2023-05-17	Sunbelt Securities, Inc.	reduced	-91.72	-224,932	42,141	0.01%
2023-05-17	Advisory Services Network, LLC	unchanged	-	32,843	69,988	-%
2023-05-17	Thrivent Financial for Lutherans	reduced	-3.39	982,000	2,179,000	-%
2023-05-16	Rockefeller Capital Management L.P.	added	0.47	447,000	607,000	-%

Latest Funds Activity

Are funds buying NEO calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own NEO

No. of Funds

Neogenomics News

Schedule 13G FIlings of Neogenomics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 10, 2023	artisan partners limited partnership	0.0%	10	SC 13G/A
Feb 09, 2023	vanguard group inc	10.83%	13,674,745	SC 13G/A
Feb 09, 2023	brown advisory inc	5%	6,337,008	SC 13G
Feb 06, 2023	wellington management group llp	0.00%	0	SC 13G/A
Jan 23, 2023	blackrock inc.	17.4%	21,932,623	SC 13G/A
Feb 04, 2022	wellington management group llp	8.99%	11,069,283	SC 13G
Feb 04, 2022	artisan partners limited partnership	6.3%	7,732,355	SC 13G
Jan 27, 2022	blackrock inc.	15.7%	19,328,254	SC 13G/A
Jan 26, 2022	blackrock inc.	15.7%	19,328,254	SC 13G
Feb 10, 2021	vanguard group inc	10.06%	11,167,578	SC 13G/A

NEO Fair Value

Recent SEC filings of Neogenomics

View All Filings

Date Filed	Form Type	Document
May 24, 2023	3	Insider Trading
May 24, 2023	4	Insider Trading
May 17, 2023	8-K	Current Report
May 15, 2023	4	Insider Trading
May 15, 2023	4	Insider Trading
May 15, 2023	4	Insider Trading
May 15, 2023	4	Insider Trading
May 15, 2023	4	Insider Trading
May 15, 2023	4	Insider Trading
May 09, 2023	10-Q	Quarterly Report

Latest Insider Trading transactions for NEO

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-05-22	TETRAULT LYNN A.	acquired	17,481	11.6	1,507	-
2023-05-01	Olivo Alicia C	sold (taxes)	-	-	-662	general counsel
2023-04-01	Kulkarni Shashikant	sold (taxes)	-	-	-3,759	chief scientific officer
2023-03-02	Dieter Cynthia J	sold (taxes)	-	-	-117	chief accounting officer
2023-03-01	Dieter Cynthia J	sold (taxes)	-	-	-880	chief accounting officer
2023-01-01	Harris Melody	acquired	-	-	108,225	president, enterprise ops
2022-12-31	Sikri Vishal	acquired	1,584	7.04	225	president, pharma services
2022-12-31	Dieter Cynthia J	sold (taxes)	-	-	-959	chief accounting officer
2022-12-05	Sherman Jeffrey Scott	acquired	-	-	133,809	chief financial officer
2022-12-01	Stone Warren	acquired	-	-	89,206	president, clinical services

About Neogenomics

Lynn A. Tetrault

www.neogenomics.com

2000

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

NEO Income Statement

2023-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Total net revenue	$ 137,220	$ 117,169
COST OF REVENUE	82,406	78,937
GROSS PROFIT	54,814	38,232
Operating expenses:
General and administrative	61,549	66,248
Research and development	7,395	7,713
Sales and marketing	16,259	16,299
Restructuring charges	4,684	0
Total operating expenses	89,887	90,260
LOSS FROM OPERATIONS	(35,073)	(52,028)
Interest (income) expense, net	(1,467)	1,301
Other expense (income), net	114	(168)
Loss before taxes	(33,720)	(53,161)
Income tax benefit	(2,925)	(3,753)
NET LOSS	$ (30,795)	$ (49,408)
NET LOSS PER SHARE
Basic (in dollars per share)	$ (0.25)	$ (0.40)
Diluted (in dollars per share)	$ (0.25)	$ (0.40)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic (in shares)	125,026	123,630
Diluted (in shares)	125,026	123,630
Clinical Services
Total net revenue	$ 114,869	$ 98,791
COST OF REVENUE	67,292	65,267
GROSS PROFIT	47,577	33,524
Pharma Services
Total net revenue	22,351	18,378
COST OF REVENUE	15,114	13,670
GROSS PROFIT	$ 7,237	$ 4,708

NEO Balance Sheet

2023-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 275,609	$ 263,180
Marketable securities, at fair value	142,306	174,809
Accounts receivable, net	118,842	119,711
Inventories	24,432	24,277
Prepaid assets	16,185	15,237
Other current assets	7,622	8,077
Total current assets	584,996	605,291
Property and equipment (net of accumulated depreciation of $138,863 and $131,930, respectively)	102,845	102,499
Operating lease right-of-use assets	93,784	96,109
Intangible assets, net	399,477	408,260
Goodwill	522,766	522,766
Other assets	5,306	5,109
Total non-current assets	1,124,178	1,134,743
Total assets	1,709,174	1,740,034
Current liabilities
Accounts payable	22,712	20,510
Accrued compensation	32,891	40,141
Accrued expenses and other liabilities	17,964	15,070
Current portion of equipment financing obligations	38	70
Current portion of operating lease liabilities	6,934	6,584
Pharma contract liabilities	6,067	7,557
Total current liabilities	86,606	89,932
Long-term liabilities
Convertible senior notes, net	536,037	535,322
Operating lease liabilities	67,319	68,952
Deferred income tax liabilities, net	31,715	34,750
Other long-term liabilities	13,035	13,055
Total long-term liabilities	648,106	652,079
Total liabilities	734,712	742,011
Commitments and contingencies (Note 11)
Stockholders’ equity
Common stock, $0.001 par value, (250,000,000 shares authorized; 127,200,491 and 126,913,992 shares issued and outstanding, respectively)	127	127
Additional paid-in capital	1,167,051	1,160,882
Accumulated other comprehensive loss	(2,834)	(3,899)
Accumulated deficit	(189,882)	(159,087)
Total stockholders’ equity	974,462	998,023
Total liabilities and stockholders’ equity	$ 1,709,174	$ 1,740,034